Astellas Pharma (OTCMKTS:ALPMY) Sees Large Volume Increase – Time to Buy?

Shares of Astellas Pharma Inc. (OTCMKTS:ALPMY) saw unusually-strong trading volume on Tuesday . Approximately 317,850 shares traded hands during trading, an increase of 212% from the previous session’s volume of 101,867 shares.The stock last traded at $14.42 and had previously closed at $14.38.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the company. Zacks Research cut Astellas Pharma from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 22nd. Citigroup downgraded Astellas Pharma from a “strong-buy” rating to a “hold” rating in a research note on Monday, January 19th. Three investment analysts have rated the stock with a Hold rating, According to data from MarketBeat.com, Astellas Pharma presently has a consensus rating of “Hold”.

Astellas Pharma Stock Down 0.1%

The company has a debt-to-equity ratio of 0.20, a quick ratio of 0.80 and a current ratio of 1.03. The business’s 50 day moving average price is $13.38 and its 200-day moving average price is $11.77. The firm has a market capitalization of $26.00 billion, a PE ratio of 30.57 and a beta of 0.17.

Astellas Pharma (OTCMKTS:ALPMY) last released its earnings results on Thursday, October 30th. The company reported $0.30 earnings per share for the quarter, beating the consensus estimate of $0.20 by $0.10. Astellas Pharma had a return on equity of 22.21% and a net margin of 6.39%.The company had revenue of $3.45 billion during the quarter, compared to the consensus estimate of $3.14 billion. As a group, equities research analysts forecast that Astellas Pharma Inc. will post 0.42 earnings per share for the current year.

Astellas Pharma Company Profile

Astellas Pharma Inc is a Tokyo-based, global pharmaceutical company traded in the United States as an American Depositary Receipt on the OTC Markets under the symbol ALPMY. The company focuses on discovering, developing and marketing prescription medicines in key therapeutic areas, including oncology, urology, immunology, neuroscience and cardiovascular/metabolic diseases. Astellas seeks to bring innovative treatments to market by combining internal research capabilities with external partnerships and collaborative agreements around the world.

Core products in Astellas’ portfolio include the immunosuppressant Prograf (tacrolimus), the overactive bladder treatments Vesicare (solifenacin) and Myrbetriq (mirabegron), and the prostate cancer therapy Xtandi (enzalutamide).